AAV is crucial in the field of uncomfortable therapy; more than 1,300 unique genetical therapy products are currently under development and almost half depend on the AAV. The ability to scale production is key to reducing costs and accelerating the process from research to commercialization.
“AAV has a efficiency and its safety profile that make it an ideal therapeutic vehicle and one of the go-to biological delivery methods for the latest advances in gene therapy,” said Amy Butler, president, biosciences, Thermo Fisher Scientific. “AAV’s new production system is part of our end-to-end workflow solutions designed to meet the growing demand for cost-effective and scalable viral vector production. Access to products and services designed specifically for cell and gene therapy research, with a focus on clinical manufacturing, enables our biotech and biopharmaceutical the partners.”
The AAV-MAX system was developed to go from shake flasks to bioreactors. Coupled with the active development of regulatory-compliant reagents, the system is designed to streamline the transition from research to commercial manufacturing. According to the company, on average, the system can save researchers and viral vector developers 25% on plasmid DNA and 50% on production costs compared to polyethyleneimine (PEI) based mammalian production systems.
More Stories
Floating Production System (FPS) Market will See Booming Opportunities for Growth and Development By 2030 | BUMI Armada Berhad, Daewoo Shipbuilding & Marine Engineering
Isotope Production System begins commercial production of
Didimo Announces $7.15M Funding to Expand 3D Avatar Production System